Efficacy and safety of aliskiren in Japanese patients with severe hypertension: An 8 week, multicenter, uncontrolled, open-label study

被引：0
|
作者：
Kushiro, T. [1 ]
Le Breton, S. [2 ]
Takabayashi, N. [3 ]
机构：
[1] Nihon Univ Surugadai Hosp, Dept Cardiol, Tokyo, Japan
[2] Novartis Pharma AG, CIS BIOS CV, Basel, Switzerland
[3] Novartis Pharma KK, Tokyo, Japan
来源：
JOURNAL OF HYPERTENSION | 2008年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S468 / S469
页数：2
相关论文
共 50 条
  • [1] Safety and Efficacy of Aliskiren/Amlodipine/Hydrochlorothiazide Triple Combination in Patients With Moderate to Severe Hypertension: A 54-Week, Open-Label Study
    Murray, Alexander V.
    Koenig, Wolfgang
    Garcia-Puig, Juan
    Patel, Samir
    Uddin, Alkaz
    Zhang, Jack
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2012, 14 (12): : 821 - 827
  • [2] EFFICACY AND SAFETY OF ALISKIREN/AMLODIPINE OR ALISKIREN/AMLODIPINE/HYDROCHLOROTHIAZIDE COMBINATIONS: A 18-WEEK, OPEN-LABEL STUDY IN PATIENTS WITH STAGE II HYPERTENSION IN THAILAND
    Vichairuangthum, Kitigon
    Chotnaparatpat, Paiboon
    [J]. JOURNAL OF HYPERTENSION, 2015, 33 : E5 - E5
  • [3] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    [J]. International Journal of Hematology, 2017, 105 : 309 - 317
  • [4] Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    [J]. International Journal of Hematology, 2017, 105 : 387 - 387
  • [5] A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
    Kobayashi, Shigeto
    Harigai, Masayoshi
    Mozaffarian, Neelufar
    Pangan, Aileen L.
    Sharma, Shringi
    Brown, L. Steven
    Miyasaka, Nobuyuki
    [J]. MODERN RHEUMATOLOGY, 2012, 22 (04) : 589 - 597
  • [6] Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study
    Hide, Michihiro
    Ohsawa, Isao
    Nurse, Christina
    Yu, Ming
    [J]. JOURNAL OF DERMATOLOGY, 2023, 50 (11): : 1381 - 1391
  • [7] LONG-TERM EFFICACY AND SAFETY OF ALISKIREN/VALSARTAN COMBINATION IN HYPERTENSIVE PATIENTS: A 54-WEEK, OPEN-LABEL STUDY
    Chrysant, S. G.
    Murray, A. V.
    Hoppe, U. C.
    Dattani, D.
    Patel, S.
    Zhang, J.
    [J]. JOURNAL OF HYPERTENSION, 2009, 27 : S281 - S281
  • [8] The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study
    Lee, Hwang-Bin
    Yoon, Bo-Hyun
    Kwon, Young-Joon
    Woo, Young Sup
    Lee, Jung-Goo
    Kim, Moon-Doo
    Bahk, Won-Myong
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 743 - 753
  • [9] The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study
    Hwang-Bin Lee
    Bo-Hyun Yoon
    Young-Joon Kwon
    Young Sup Woo
    Jung-Goo Lee
    Moon-Doo Kim
    Won-Myong Bahk
    [J]. Clinical Drug Investigation, 2013, 33 : 743 - 753
  • [10] Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
    Nakao Iwata
    Jun Ishigooka
    Ichiro Naoi
    Masahiro Matsumoto
    Yuichi Kanamori
    Hiroshi Nakamura
    Teruhiko Higuchi
    [J]. CNS Drugs, 2020, 34 : 103 - 116
12345